Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $41

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and raises the price target from $35 to $41.